Abstract Here we present the principles and steps of a protocol that we have recently developed for the differentiation of hES/iPS cells into the authentic human striatal projection medium spiny neurons (MSNs) that die in Huntington's Disease (HD). Authenticity is judged by the convergence of multiple features within individual cells. Our procedure lasts 80 days and couples neural induction via BMP/TGF-β inhibition with exposure to the developmental factors sonic hedgehog (SHH) and dickkopf1 (DKK-1) to drive ventral telencephalic specification, followed by terminal differentiation [1] . Authenticity of the resulting neuronal population is monitored by the appearance of FOXG1 + /GSX2 + progenitor cells of the lateral ganglionic eminence (LGE) at day 15-25 of differentiation, followed by appearance of CTIP2-, FOXP1-and FOXP2-positive cells at day 45. These precursor cells then mature into MAP2 + /GABA + neurons with 20 % of them ultimately co-expressing the DARPP-32 and CTIP2 diagnostic markers and carrying electrophysiological properties expected for fully functional MSNs.
Introduction
Human pluripotent stem (hPS) cells (both embryonic and induced) have emerged as a powerful tool for developmental biology studies, genetic and chemical screens, and regenerative medicine for neurological diseases, as they can generate different neuronal subtypes [2] . In particular, in the last 2 years, a number of important protocols have been developed largely based on the knowledge that, in vivo, specific neural progenitors are induced along the rostro-caudal and dorsal-ventral axes by secreted morphogens. The combined and specific application of a few of these morphogens, such as SHH, FGF8, retinoic acid, wingless-type MMTV integration site (WNT) family and its inhibitors, has made it possible to produce spinal motor neurons, neocortical progenitors and neurons [3] , forebrain glutamatergic and cholinergic neurons from human pluripotent stem cells [3, 4] . Authentic dopaminergic mesencephalic neurons have also been obtained through induction of floor plate fate and application of ventralizing signals [5, 6] .
Earlier attempts at obtaining differentiation into striatal neurons have made use of an undefined stromal co-culture method to which hES cells were exposed [7] . Subsequently, a culture system involving embryoid bodies formation and Alessia Delli Carri and Marco Onorati contributed equally to this work. exposure to 200 ng/ml SHH was used to obtain transplantable LGE-like progenitors [8] . However, both methods failed to reveal a ventral telencephalic character in the emerging progenitors nor they demonstrated the acquisition of a distinctive MSN character in the generated neurons, that were not deeply characterized from a neurochemical and/or electrophysiological point of view. In contrast, we have recently validated and published a procedure for the generation of authentic human MSNs from both hES and hiPS cells, based on an ontogeny-recapitulating three-step method that incorporates neural induction, patterning, and terminal differentiation [9] . Here we provide a detailed account of the procedure. The first step towards the development of the mature forebrain is neural induction, which generates the neural plate, begins during gastrulation, and at a general level is repressed by TGF-β signaling. Accordingly, several authors have used the dual SMAD inhibition strategy [1] to efficiently drive the formation of anterior neuroepithelial stem cells from hES cells. In our protocol we have successfully adopted this strategy to obtain anterior neural progenitors.
In vivo, Shh is expressed in the ventral telencephalon and hypothalamus and is essential to the regionalization of the subpallium [10, 11] while along the dorsal midline, secreted molecules of the bone morphogenetic proteins (BMP) and WNT families control patterning of the medial and dorsal pallium. These telencephalic patterning centers initiate regionalization of the telencephalon by inducing graded expression of transcription factors (TFs) in neural progenitors across the rostro-caudal and dorso-ventral axes [12] . We found that addition to the neuroectodermal cultures of the secreted molecules SHH and DKK-1 (a WNT inhibitor) fully recapitulate their in vivo functions, as judged by the appearance of FOXG1 + /GSX2 + ventral telencephalic progenitors from the neuralizing hES cells. We also found that at subsequent days of in vitro differentiation cells mature into electrophysiological active DARPP-32 + /CTIP2 + striatal MSNs, as found in vivo in humans [9] . Our protocol generates a large amount of GABAergic neurons (around 80 %) with a large portion of them being CTIP2 + /calbindin + . Most importantly, at day 80, 20 % of the neurons are DARPP-32 + MSNs co-expressing CTIP2 and carrying dopamine D2 and adenosine A2a receptors. Upon depolarization, these neurons elicit trains of action potentials and show consistent dopamine-dependent neuromodulation and synaptic activity. Importantly, in the described protocol, the progressive maturation of the cells is accompanied by a timedependent modulation of the expression of specific progenitor and neuronal TFs and neurochemical markers and similar fluctuations were observed in vivo during human fetal brain development. For instance, our culture system generates an enriched population of GSX2 + LGE progenitors starting from 2 weeks of neural induction, whereas PAX6 is expressed before SOX1 and FOXG1, and DARPP-32 follows CTIP2 expression during differentiation.
We therefore propose the protocol described below as suitable for the derivation of authentic LGE progenitor cells and functional MSNs from hES and iPS cells. the next 5 days, collect every day the medium and replace it with 20 ml fresh complete hES/iPS KSR Medium. Filter through 0.22 μm-sterile filter. Store conditioned Medium at 4°C for up to 1 week, or alternatively at −20 or −80°C for long-term storage. 
Materials, Reagents and Solutions

Materials
Methods
Protocol A. Preparation of the Cultures of hPS Cells
Here we describe the routine culture of hES cells and fibroblasts-derived hiPS cells. In our striatal differentiation protocol we employed hES/iPS cells cultured either on feeder cells or on Matrigel in feeder-free condition (see Note 1). We have successfully used our protocol to differentiate the H9 hES cell line cultured on MEF CD1 strain or on Matrigel, the HS401 hES cell line cultured on foreskin FS human feeder cells, the DF3F hiPS cell line cultured on MEF CD1 strain (as described in Camnasio et al., 2012 [13] where it is named WTiPS 3 F-1).
Culture of hPS Cells on Feeder Cells In this section we describe our ontogeny-recapitulating protocol for the direct differentiation of hPS cells towards striatal MSNs [9] . This is a multistep procedure composed of three different phases ( Fig. 1 −2) . 43. Change the medium every day with feeder-CM containing 10 ng/ml FGF-2 until they reach 100 % confluence, at which point the medium should be switched to neural induction medium.
B2. Neural induction (from day 0 to day 12) and patterning (from day 5 to day 26)
44. Day 0: when cells have reached~100 % confluence (Fig. 2a) , add 2 ml (for a well of a 6-well plate, 3 ml for a 60 mm-dish) of KSR medium + n o g g i n 5 0 0 n g / m l ( a l t e r n a t i v e l y u s e Dorsomorphin 5 μM instead of noggin during the neural induction step) + SB431542 10 μM. 45. Day 3: carefully aspirate the medium and replace it entirely with KSR Medium + noggin 500 ng/ml + SB431542 10 μM (Day 3-5 Medium). 46. Day 5: carefully aspirate the medium and replace it entirely with 75 % KSR + 25 % N2 Medium + noggin 500 ng/ml + SB431542 10 μM. Starting from this day add SHH C-25II 200 ng/ml + DKK-1 100 ng/ml (Day 5-7 Medium). 47. Day 7: carefully aspirate the medium and replace it entirely with 50 % KSR + 50 % N2 Medium + noggin 500 ng/ml + SB431542 10 μM + SHH C-25II 200 ng/ml + DKK-1 100 ng/ml (Day 7-9 Medium). 48. Day 9: carefully aspirate the medium and replace it entirely with 25 % KSR medium + 75 % N2 Medium + noggin 500 ng/ml + SB431542 10 μM + SHH C-25II 200 ng/ml + DKK-1 100 ng/ml (Day 9-11 Medium). 49. Day 12: carefully aspirate the medium and replace it entirely with 100 % N2 Medium + SHH C-25II 200 ng/ml + DKK-1 100 ng/ml (Day 12-15 Medium) (see Note 3). 50. Between day 12 and day 15, partially change the medium once. Keep 1/3 of medium and add 2/3 of fresh medium composed of 100 % N2 medium + SHH C-25II 200 ng/ml + DKK-1 100 ng/ml. The morphogens SHH C-25II (200 ng/ml) and DKK-1 (100 ng/ml) are maintained until day 26.
Rosette Replating
51. Between days 12 and 15, fields full of rosettes become morphologically visible (Fig. 2b, c) . To allow the cells to terminally differentiate, they need to be replated. Add 37°C Accutase and incubate at 37°C in 5 % CO 2 for 15-20 min. Check every 5 min the detaching of the cells. To facilitate clump dissociation, gently shake the dish without pipetting, to avoid excessive cell death. 55. Prepare Matrigel-coated dishes by carefully aspirating all liquid from the dish, taking care not to touch the surface (alternatively use poly-D-lysine/laminin-coated dish). 56. Plate 0.65×10 5 cells/cm 2 in a single drop of 40-50 μl into a well of a 12-well plate. Wait at maximum 15 min to allow the cells to adhere and then add 300 μl of NBB 30 medium supplemented with Y-27632 10 μM (0.2 ml for well of 24-well plate, 1 ml for well of 6-well plate). 57. Transfer dishes carefully in a 37°C, 5 % CO 2 incubator and leave overnight (see Note 4). 58. The day after, check that cells have attached and add NBB 30 medium to a final volume of 1 ml per well for a 12-well plate (or 0.5 ml for a well of a 24-well plate, 2 ml for a well of a 6-well plate). For the amount of morphogens to be added consider the final volume, including the medium present since the day before. During differentiation several classes of neural progenitor/ precursor cells arise which eventually give rise to fully differentiated mature neurons. The identity and proportions of these neuronal subclasses can be defined by the combinatorial expression of a core set of TFs and diagnostic markers combined with electrophysiological measurements. We have identified time points during differentiation allowing to monitor the progression of the cultures towards MSN generation:
62. Day 5-15, from pluripotency to neuropotency. During this transition neuroectodermal and neuroepithelial cells begin to appear. The first marker to appear at day 5 is PAX6 with 65 % of the cells becoming positive at day 15, when also SOX1 is expressed (Fig. 2b, c and d , Tables 1 and 2 ). At day 15 several rosettes markers such as DACH1, LIX1, LMO3 and MSX1 are also detected by RT-PCR (Table 1) . During this transition, OTX2 is maintained throughout while OCT4 is no longer detected at day 15 (Tables 1 and 2 ). 63. Day 15, emergence of markers of telencephalic and ventral fate. Rosette-stage telencephalic neural progenitors appear at around 15-20 days of differentiation and can be recognized by the expression of FOXG1 (Fig. 2e , Tables 1 and 2 ) and of the LGE marker GSX2 (Fig. 2f , Table 2 ). 58 % of the cells express the telencephalic markers FOXG1 while 64 % express the ventral telencephalic TF GSX2. At the same time point expression of DLX5, DLX6 and ISL1 was found by RT-PCR (Table 1) . 64. Day 45, acquisition of a striatal identity. At this time point we revealed the acquisition of a striatal identity that is verified by the presence of a combination of diagnostic postmitotic striatal markers. Starting from this time point the cells show expression of mature neuronal proteins such as MAP2 and TAU, GABAergic markers such as GAD65/67 and GABA, striatal associated markers such as calbindin, FOXP1, FOXP2, CTIP2, ARPP-21 and DARPP-32 (Fig. 3a-f , Tables 1 and 2 ). We suggest measuring the co-expression of these markers in the presumptive MSN in order to define the definitive striatal character of a neuron (Fig. 3g , Table 2 and see Note 6). DARPP-32 expression alone is in fact not diagnostic of human MSNs since DARPP-32 + neurons are found also outside the striatum. We suggest verifying the co-expression of at least GABA/DARPP-32, G A D 6 5 -6 7 / D A R P P -3 2 , C T I P 2 / D A R P P -3 2 , FOXP1/CTIP2 in order to quantify the percentage of MSNs generated at the end of differentiation. considered), whose MSN identity is confirmed by the co-expression with CTIP2 ( Fig. 3 a-g ).
Striatal interneurons at day 80 are represented by <15. (Fig. 4a, b) . The presence of GABA-evoked currents, I A potassium current (Fig. 4c, d ) and dopamine neuromodulation (as described in our original report Delli Carri et al. 2013 [9] ) will further ascertain the electrophysiological signature of GABAergic striatal projection neurons (see below).
Immunofluorescence Analysis to Investigate Cell Identity (Table 2 ) diluted in primary blocking solution at 4°C overnight. 72. After three washes with PBS 1X, incubate for 1 h at RT with the appropriate secondary antibody and counterstain the nuclei with Hoechst, diluted in the secondary antibody solution (Table 2) .
73.
After three washes with PBS 1X and mounting proceed with the co-localization studies with in vivo validated antibodies as reported in Table 2 and described in Delli Carri et al. (2013) [9] (see Note 6).
Electrophysiological Characterization of Striatal MSNs Derived from hPS Cells
The active and passive intrinsic properties of the developing hPS cell-derived MSNs and their spontaneous and pharmacologically-evoked synaptic currents are obtained using the whole-cell patch-clamp technique both in voltage-and current-clamp mode. To monitor the electrophysiological differentiation of the neurons, the recordings are repeated at intermediate time points and at the end of the differentiation process. The MSN phenotype of the recorded cells can be confirmed by the co-detection of the biocytin (intracellularly injected through the patch-clamp pipette during recording) and the expression of DARPP-32 or CTIP2 in the same cells.
74. Before recordings: a) the extracellular solution (Solution 2, Table 3 ) should be kept at room temperature for at least 30 min. Biocytin (1 %), Na 2 -ATP, Creatine phosphate and Na 3 -GTP should be freshly added to the intracellular solution immediately before the beginning of the experiments. b) A set of borosilicate glass pipettes can be prepared using a puller. When filled with the intracellular solution the pipette resistance should range between 3,5 and 4 MΩ. C) The perfusion system should be filled with specific solutions and drugs and the functionality of the electrovalves checked. 75. 2.5 ml of the external solution (Solution 2, Table 3 ) is added to a 35-mm Petri dish. Table 3 ). 79. Following giga-seal and whole cell configuration, a −10 mV step protocol should be applied. The integration of the capacitive current is used to determine the membrane capacitance and is performed with the software Clampfit (Molecular Devices). 80. Capacitance compensation and series resistance correction should be performed. 81. In voltage-clamp mode a protocol is run to detect the presence of Na + and delayed-rectifier K + currents by holding the membrane potential at −90 mV and giving a series of progressively increasing test steps from −80 mV to +40mV. 82. To record the resting membrane potential the system should be switched to the current-clamp mode. To characterize the voltage response and the firing properties, maintaining the current-clamp configuration, a series of sub-and suprathreshold depolarizing and hyperpolarizing steps of current (duration 1 or 3 s) are applied from a membrane potential of −80/-70 mV. A delay in the first spike generation would suggest the presence of the I A potassium current that will be verified by applying 4-AP (1 mM), a selective blocker of A-type K + channels, and determine a shortening time in the generation of the first spike. Dopaminergic modulation of membrane potential through D2 receptors should be checked for by applying the selective agonist (quinpirole, 5 μM). 83. Delayed rectifier and fast potassium currents can be checked for.
Steps from 68 to 74 should be repeated and tetrodotoxin (TTX 1 μM) added to the extracellular solution (Solution 4, Table 3 ). Here is the protocol: following holding the membrane potential at −110 mV for 1 s, tests potentials should be applied between −70 to +40 mV (step size 10 mV). The fast inactivating transient (I A ) K + current is completely abolished when the test potential is preceded by a 50 ms prepulse at −40 mV or when the extracellular solution is supplied with 4-AP (1 mM). Under these conditions, only the slow delayed rectifier K + current component could be elicited. The fast inactivating K + current could be isolated by subtracting the traces recorded after the prepulse to −40 mV or during 4-AP perfusion from those elicited in normal conditions. 84. GABAergic synaptic currents, spontaneously evoked and pharmacologically-elicited by locally applying GABA (20 μM) should be checked for. Repeat step from 68. to 74. The extracellular solution (Solution 2, Table 3 ) is added with CNQX (10 μM) and CPP (30 μM) to block AMPA and NMDA receptors respectively. Due to the photosensitivity of CNQX, these experiments should be performed at very low environmental light intensity. The intracellular solution (Solution 1, Table 3) should contain lidocaine to block, intracellularly, the Na + channels. A possible modulatory effect of dopamine on GABA-elicited currents can be checked for by applying dopamine (100 μM). 85. At the end of the electrophysiological recordings the extracellular solution can be carefully removed from the Petri dish and fixed for immunofluorescence reaction. The recorded cells will be identified with streptavidin-conjugated to fluorochrome and visualized using a confocal microscopy.
Notes
Note 1
The table lists the different media used for the culture of the hPS cell lines employed in this work.
Note 2
We have tested several substrates for the neural induction phase:
(i) Laminin (10 μg/ml): the cells remain poorly attached until day 12, usually they detach before day 9.
(ii) Poly-D-lysine: on this substrate the hPS cells we have tested do not proliferate nor reach a good confluence necessary for neural induction but rather degenerate soon after plating.
(iii) Poly-ornithine: also in this case, we noticed that cells detach at around day 5. (iv) As an alternative we plate cells on Matrigel reduced factors-coated dishes.
Note 3
As an alternative, it is possible to use the same medium from day 0 to day 12 composed of: DMEM/F12 #21331, N-2 1:100, B-27 1:100, insulin 20 ng/ml, supplemented with SB431542 10 μM + noggin 500 ng/ml (or Dorsomorphin 5 μM instead of noggin). The use of this medium avoids excessive cell proliferation during neural induction, and can be used also with Matrigel reduced factors. Media containing KSR have a higher protein content and chemical buffering capacity. In a medium devoid of KSR the concentration of some chemical factors (such as dual SMAD inhibitors) may be reduced, because they might result in toxicity in more sensitive cell lines [14] .
Note 4
For replating, as alternative from step 51 to 56 follow: Starting from the replating step it is possible to add DAPT 10 μM to NBB medium for maximum two weeks (depending on the maturation state of the cells). This treatment accelerates neuronal differentiation [5] . All the critical and diagnostic antibodies employed in the work for the characterization of generating telencephalic progenitors and MSNs were validated on 11 week-old human fetal brain sections [9] . This standardized procedure avoids using unspecific antibodies and allows to have a validated tool for characterization of the differentiation process.
Note 7
Some antibodies require specific antigen retrieval procedures, such as FOXG1: unmasking with 1mM EDTA for 10 min at 65°C and wash with PBSX.
